At the Myocarditis Foundation, we focus on conditions that affect the heart, including pericarditis. Pericarditis is when the lining around the heart becomes inflamed, and it’s a problem that often…

At the Myocarditis Foundation, we focus on conditions that affect the heart, including pericarditis. Pericarditis is when the lining around the heart becomes inflamed, and it’s a problem that often…
On Thursday February 20th, the Humble ISD Mental Health and Wellness Team held a Health Fair that the Myocarditis Foundation participated in. There were over 600 attendees (parents, grandparents, teachers,…
For individuals suffering from severe heart failure, mechanical heart devices can be lifesaving. These devices either assist the heart in pumping blood or replace it entirely, depending on the severity…
Immunotherapy has revolutionized cancer treatment by harnessing the body’s immune system to fight cancer cells. However, a significant concern has emerged: some patients receiving immune checkpoint inhibitors (ICIs) develop Immunotherapy-…
Kiniksa Pharmaceuticals is looking to create a Virtual Recurrent Pericarditis Advisory Board. We’re inviting individuals affected by recurrent pericarditis, both in the US and internationally, to participate in this important…
The Myocarditis Foundation was proud to support and cheer on runners at the recent Houston Marathon this past weekend! We were especially excited to have a dedicated runner representing the…
The Myocarditis Foundation has made strides in education, patient support, and research. But to ensure that our mission continues to impact future generations, we rely on generous supporters who believe…
We are excited to share the results from Cardiol Therapeutics’ MAvERIC-Pilot clinical trial, which were recently presented at the American Heart Association Scientific Sessions in November. This trial focused on…
All of us at the Myocarditis Foundation would like to extend our heartfelt thanks for 20 years of unwavering support and dedication! Our mission to raise awareness, provide support, and…
Recurrent pericarditis, a condition affecting approximately 40,000 people in the United States, involves inflammation of the pericardium, the protective sac surrounding the heart. This condition can cause chest pain and, in some cases, lead to fluid buildup around the heart, which can severely impact a patient’s health and well-being.
To address this critical issue, the Myocarditis Foundation is proud to highlight an initiative aimed at enhancing care and outcomes for those suffering from recurrent pericarditis. This three-year initiative, supported by Kiniksa Pharmaceuticals and the American Heart Association, is designed to equip healthcare providers with the latest science and best practices to improve diagnosis and treatment. The initiative will also create patient-focused resources that educate and empower those affected by this often-overlooked condition.
The initiative focuses on three key areas:
Recurrent pericarditis often goes undiagnosed or is not adequately treated, which can significantly affect a patient’s emotional and physical health. By improving awareness and treatment methods, this initiative seeks to reduce the burden on patients and enhance their quality of life.
As part of this effort, the initiative is partnering with 15 leading healthcare facilities across the U.S. These hospitals will serve as champions, implementing key activities and sharing best practices within a collaborative network of experts in pericarditis care. The participating sites include:
These hospitals will be instrumental in improving the quality of care for patients through shared knowledge and resources. By working closely with healthcare professionals across the nation, the initiative will ensure that patients with recurrent pericarditis have access to expert care and the best possible outcomes.
Pericarditis can be a one-time acute episode or a recurring issue, with about 30% of individuals experiencing multiple episodes. Despite its prevalence, around 90% of cases have no known cause. Common treatments include anti-inflammatory medications like aspirin or NSAIDs, and for more severe cases, corticosteroids or interleukin-1 (IL-1) inhibitors may be used to manage symptoms and prevent recurrence.
The Myocarditis Foundation is committed to improving the lives of individuals impacted by heart conditions like recurrent pericarditis. Through education, advocacy, and collaboration with leading healthcare institutions, we aim to bring more attention to this condition and ensure patients receive the care they need.